Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$194.96
+2.3%
$187.13
$163.81
$218.66
$336.71B0.486.27 million shs6.04 million shs
Anthem Inc stock logo
ANTM
Anthem
$0.00
$355.43
$533.68
$116.34BN/A1.21 million shs1.27 million shs
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$157.72
+0.9%
$153.73
$140.68
$169.99
$379.41B0.418.03 million shs6.72 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$71.06
+2.0%
$70.36
$57.00
$143.49
$311.17B0.647.28 million shs6.37 million shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
+2.21%+2.88%+2.98%+11.47%+15.95%
Anthem Inc stock logo
ANTM
Anthem
0.00%0.00%0.00%0.00%0.00%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
+1.05%+1.16%+0.81%+4.02%+5.56%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
+1.80%+2.90%-10.50%+9.73%-50.22%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AbbVie Inc. stock logo
ABBV
AbbVie
4.9441 of 5 stars
3.45.03.33.94.01.71.3
Anthem Inc stock logo
ANTM
Anthem
N/AN/AN/AN/AN/AN/AN/AN/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
4.8368 of 5 stars
2.35.04.23.93.01.71.9
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
4.7877 of 5 stars
4.15.02.50.03.50.03.1
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AbbVie Inc. stock logo
ABBV
AbbVie
2.81
Moderate Buy$211.298.37% Upside
Anthem Inc stock logo
ANTM
Anthem
0.00
N/AN/AN/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
2.55
Moderate Buy$171.008.42% Upside
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
2.27
Hold$112.0057.62% Upside

Current Analyst Ratings Breakdown

Latest ANTM, JNJ, ABBV, and NVO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/10/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingUnderperform ➝ Underperform
7/10/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$169.00 ➝ $171.00
6/11/2025
AbbVie Inc. stock logo
ABBV
AbbVie
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold$205.00
6/9/2025
AbbVie Inc. stock logo
ABBV
AbbVie
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold$204.00
6/5/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$181.00
5/14/2025
AbbVie Inc. stock logo
ABBV
AbbVie
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$210.00 ➝ $205.00
5/13/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/13/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform$169.00 ➝ $153.00
5/8/2025
AbbVie Inc. stock logo
ABBV
AbbVie
BNP Paribas
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
4/29/2025
AbbVie Inc. stock logo
ABBV
AbbVie
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$214.00 ➝ $216.00
4/28/2025
AbbVie Inc. stock logo
ABBV
AbbVie
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$204.00 ➝ $205.00
(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AbbVie Inc. stock logo
ABBV
AbbVie
$56.33B6.11$15.27 per share12.77$1.90 per share102.61
Anthem Inc stock logo
ANTM
Anthem
N/AN/AN/AN/AN/AN/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$89.33B4.25$13.24 per share11.91$29.69 per share5.31
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$42.12B7.53$3.98 per share17.86$4.66 per share15.25
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AbbVie Inc. stock logo
ABBV
AbbVie
$4.28B$2.3582.9613.951.297.31%412.03%13.11%7/31/2025 (Estimated)
Anthem Inc stock logo
ANTM
Anthem
N/A$32.5414.83N/AN/AN/AN/AN/AN/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$14.07B$8.9917.5414.252.3624.42%33.46%13.30%7/16/2025 (Estimated)
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$14.64B$3.3821.0215.251.3634.52%80.94%24.23%8/6/2025 (Estimated)

Latest ANTM, JNJ, ABBV, and NVO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.89N/AN/AN/A$77.51 billionN/A
7/24/2025Q2 2025
AbbVie Inc. stock logo
ABBV
AbbVie
$3.24N/AN/AN/A$14.93 billionN/A
7/16/2025Q2 2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.65N/AN/AN/A$22.85 billionN/A
5/7/2025Q1 2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.92$0.92N/A$0.92N/A$11.87 billion
4/25/2025Q1 2025
AbbVie Inc. stock logo
ABBV
AbbVie
$2.40$2.46+$0.06$0.72$12.91 billion$13.34 billion
4/15/2025Q1 2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.59$2.77+$0.18$4.54$21.65 billion$21.89 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AbbVie Inc. stock logo
ABBV
AbbVie
$6.563.36%N/A279.15%53 Years
Anthem Inc stock logo
ANTM
Anthem
$5.121.06%N/A15.73%N/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$5.203.30%N/A57.84%64 Years
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$1.642.31%N/A48.52%N/A

Latest ANTM, JNJ, ABBV, and NVO Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/20/2025
AbbVie Inc. stock logo
ABBV
AbbVie
quarterly$1.643.54%7/15/20257/15/20258/15/2025
4/15/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
quarterly$1.303.37%5/27/20255/27/20256/10/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AbbVie Inc. stock logo
ABBV
AbbVie
44.14
0.76
0.64
Anthem Inc stock logo
ANTM
Anthem
N/AN/AN/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.49
1.26
1.03
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.70
0.74
0.56

Institutional Ownership

CompanyInstitutional Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
70.23%
Anthem Inc stock logo
ANTM
Anthem
N/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
69.55%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
11.54%

Insider Ownership

CompanyInsider Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
0.25%
Anthem Inc stock logo
ANTM
Anthem
N/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.16%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.07%
CompanyEmployeesShares OutstandingFree FloatOptionable
AbbVie Inc. stock logo
ABBV
AbbVie
55,0001.77 billion1.76 billionOptionable
Anthem Inc stock logo
ANTM
Anthem
N/A241.09 millionN/AOptionable
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
138,1002.41 billion2.40 billionOptionable
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
77,3494.47 billion4.46 billionOptionable

Recent News About These Companies

Novo Nordisk: Reclaiming Market Share
TD Cowen Keeps Buy on Novo Nordisk (NVO)
Novo Nordisk A/S (NYSE:NVO) Shares Up 1.6% - Still a Buy?
Novo Nordisk Seeks EU Approval for Higher Wegovy Dose

New MarketBeat Followers Over Time

Media Sentiment Over Time

AbbVie stock logo

AbbVie NYSE:ABBV

$194.96 +4.34 (+2.28%)
Closing price 07/10/2025 03:59 PM Eastern
Extended Trading
$194.78 -0.19 (-0.09%)
As of 07:55 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Anthem stock logo

Anthem NYSE:ANTM

Elevance Health, Inc. operates as a health company, which engages in improving lives and communities, and making healthcare simpler. The firm supports consumers, families, and communities across the entire care journeyconnecting them to the care, support, and resources they need to lead healthier lives. It offers health plans and clinical, behavioral, pharmacy, and complex-care solutions which promote whole health. The company was founded in 1944 and is headquartered in Indianapolis, IN.

Johnson & Johnson stock logo

Johnson & Johnson NYSE:JNJ

$157.72 +1.44 (+0.92%)
Closing price 07/10/2025 03:59 PM Eastern
Extended Trading
$157.26 -0.46 (-0.29%)
As of 07:55 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Novo Nordisk A/S stock logo

Novo Nordisk A/S NYSE:NVO

$71.06 +1.37 (+1.96%)
Closing price 07/10/2025 03:59 PM Eastern
Extended Trading
$70.19 -0.87 (-1.22%)
As of 07:56 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.